Geron Corporation (NASDAQ:GERN) will be releasing its earnings data after the market closes on Wednesday, August 9th. Analysts expect Geron Corporation to post earnings of ($0.05) per share for the quarter.
Geron Corporation (NASDAQ:GERN) traded up 0.90% during trading on Monday, reaching $2.24. 182,013 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $2.80 and its 200-day moving average is $2.48. Geron Corporation has a 12-month low of $1.81 and a 12-month high of $3.15. The company’s market cap is $356.55 million.
Several equities research analysts have recently issued reports on GERN shares. Zacks Investment Research upgraded shares of Geron Corporation from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research report on Thursday, June 15th. Piper Jaffray Companies restated an “overweight” rating and issued a $5.00 price target on shares of Geron Corporation in a research report on Wednesday, April 12th. Stifel Nicolaus restated a “hold” rating and issued a $2.50 price target on shares of Geron Corporation in a research report on Wednesday, April 12th. BidaskClub cut shares of Geron Corporation from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, FBR & Co restated a “buy” rating on shares of Geron Corporation in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $3.88.
About Geron Corporation
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
What are top analysts saying about Geron Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron Corporation and related companies.